Infectious Disease Control

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today...

2022-01-12 20:43 3003

Singapore biotech firm JN Medsys develops a PCR test kit that specifically detects for the Omicron variant with high accuracy

SINGAPORE, Jan. 12, 2022 /PRNewswire/ -- Singapore-based biotech firm, JN Medsys announces that it has developed a new PCR kit that detects for SARS-CoV-2 and identifies if the Omicron variant is present. It can be used on upper respiratory samples and the results can be available in just 1 hour....

2022-01-12 18:18 2296

BGI Genomics, Chinese gene test company, showcases high-throughput COVID testing air lab at Dubai World Expo

DUBAI, UAE, Jan. 12, 2022 /PRNewswire/ -- From January 11 to 13, a model of BGI Genomics' Huo-Yan Air Laboratory, was showcased at the China Pavilion of Dubai World Expo. With the continuing spread of COVID-19 worldwide, the Huo-Yan Air Laboratory, which can be set up anywhere in a very...

2022-01-12 17:18 2739

MGI Aims to Boost its Market Share through Participation at Expo 2020 Dubai's Guangdong Week

DUBAI, UAE, Jan. 11, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) is aiming to boost its market share in theMiddle East and Asia through participation at Guangdong Week, a dedicated event taking place at the world exhibition's China Pavilion fromJanuary 11-13. The ...

2022-01-11 14:00 2609

Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod

* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...

2022-01-11 09:00 3088

COVID-19 Oral Vaccine and Antibody Booster: B. subtilis Spores, Biotechnology Breakthrough by DreamTec

HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Vaccines have been a trending topic ever since the coronavirus outbreak two years ago. DreamTec Research Limited (DreamTec,http://www.dreamtec.hk ) has its major breakthrough in developing a COVID-19 oral vaccine. In its recently pu...

2022-01-05 10:00 5281

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

- Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand - ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection - ASC11 is ...

2022-01-03 08:30 4596

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India

GAITHERSBURG, Md. and PUNE, India, Dec. 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine m...

2021-12-29 03:57 4722

ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and Omicron

Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp). The virus is incapable of developing resistance to favipiravir even with long-term exposure on infect...

2021-12-27 21:20 3671

Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2021-12-27 18:45 4512

Documentary Zhong Nanshan/ZNS Aired on Discovery Channel in Southeast Asia

GUANGZHOU, China, Dec. 27, 2021 /PRNewswire/ -- On December 28, 2021, the single-episode character documentaryZhong Nanshan/ZNS, jointly produced by Guangdong Radio and Television and the pioneering global entertainment document provider, Discovery Inc., was broadcast on Discovery Channel inSouth...

2021-12-27 11:11 4041

COVID-19 Vaccine Developed by WestVac BioPharma Has High Titer Neutralizing Antibodies Against Omicron

CHENGDU, China, Dec. 24, 2021 /PRNewswire/ -- WestVac BioPharma Co., Ltd. has achieved a significant progress in the second generation COVID-19 vaccine against the Omicron mutant strain. The vaccine belongs to the latest fifth generation vaccine technology, targeting the S-RBD protein of the COV...

2021-12-24 19:57 8084

Novavax and SK bioscience Expand Manufacturing Agreement

- Novavax secures additional manufacturing capacity through 2022 - SK bioscience secures long-term license to supply NVX-CoV2373 for the Korean market GAITHERSBURG, Md., Dec. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializin...

2021-12-24 07:30 4028

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise...

2021-12-23 05:54 4448

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine

- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older - SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows grant of WHO Emerg...

2021-12-22 09:31 4597

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine

- Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketedby Serum Institute of India as Covovax™ - EUL by WHO is a prerequisite for exports to numerous countri...

2021-12-21 03:33 4056

European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

* Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use inEurope * Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 * Authorization follows positive r...

2021-12-21 03:28 4322

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

* European Commission decision on conditional marketing authorization expected imminently * Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available inEurope GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NV...

2021-12-20 21:34 3970

Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

The SPIKEVAX® brand name was developed in partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related name development MIAMI, Dec. 20, 2021 /PRNewswire/ -- Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 v...

2021-12-20 09:00 4337

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

* First EUL granted by WHO for a protein-based COVID-19 vaccine * EUL vaccine manufactured and marketed by SII as COVOVAX™ * WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review GAITHERSBURG, Md. and PUNE, India, Dec. 20, 2021 ...

2021-12-20 08:24 5119
1 ... 21222324252627 ... 35